HICKSVILLE, NY -- July
02, 2019 -- InvestorsHub NewsWire -- Canbiola,Inc.
(OTCQB: CANB)(“Canbiola” or
the “Company”), a developer, manufacturer and seller of a
variety of Cannabidiol (Hemp) based products such as oils, creams,
moisturizers, chews, isolate, gel caps, and concentrate, announced
today that its presentation from its Annual Shareholder Meeting
held on Friday, June 14, is now publicly
available.
We encourage you to read
the filing at:
https://www.sec.gov/Archives/edgar/data/1509957/000149315219009362/0001493152-19-009362-index.htm
Canbiola Chief
Executive Officer Marco Alfonsi commented, “We want to thank all of
our shareholders, especially the 100+ that attended our meeting a
couple of weeks ago. Our entire team was thrilled with the turn out
and enthusiasm. We provided background on where and how we have
gotten to this point, but more importantly our vision for where we
are going and how we expect to get there. It was great to see and
hear from our Executive Management Team, Board of Directors,
Corporate Advisory Board, Medical Advisory Board and employees. We
look forward to continuing our high degree of transparency and
communication as we progress our business and capital markets
strategy.”
A video of the entire
shareholder meeting is available via the following
link:
https://drive.google.com/file/d/1d6B0W8U5sfmL9Mr8BUixlOIJ1pKI_ixP/view?usp=sharing
About Canbiola,
Inc.
Canbiola,
Inc. (OTCQB: CANB) is a
developer, manufacturer and seller of a variety of Cannabidiol
(Hemp) based products such as oils, creams, moisturizers, chews,
isolate, gel caps, and concentrates. Canbiola has developed its own
line of proprietary products as well as seeking synergistic value
through acquisitions in the hemp CBD industry. While cannabis is
currently federally illegal and has legalized for medical and/or
recreational purposes in only a limited number of states, hemp has
been removed as a Schedule 1 narcotic under the Controlled
Substances Act. CANB’s products are derived from hemp and generally
considered legal, although potentially subject to
regulation. Hemp CBD is the non-psychoactive component
(No THC) used for of pain relief, inflammation, and wellness
programs. For more information about Canbiola, Inc.,
please visit: https://canbiola.com.
Additionally, Canbiola’s
wholly owned subsidiary Pure Health Products, based in Lacey, WA,
is its prime development laboratory and production
facility. Canbiola’s Duramed division has recently
rolled out a durable medical device via its Doctor network to treat
patients with injuries via application of an in-home ultrasound
sustained acoustic device (SAM) for pain and inflammation
reduction.
Forward-Looking
Statements
Forward-looking statements
and risks and uncertainties discussed in this letter contain
forward-looking statements. The words "anticipate," "believe,"
"estimate," "may," "intend," "expect," and similar expressions
identify such forward-looking statements. Expected, actual results,
performance, or achievements could differ materially from those
contemplated, expressed, or implied by the forward-looking
statements contained herein. Forward-looking statements are subject
to a number of risks and uncertainties, including but not limited
to, risks and uncertainties associated with, among other things,
the impact of economic, competitive, and other factors affecting
our operations, markets, products, and performance. The matters
discussed herein should not be construed in any way, shape or
manner of our future financial condition or stock
price.
Follow Canbiola
on:
Twitter
@CanbiolaHealth
Instagram @canbiola.inc or
@canbiola_cbd or @canbiola_medical_cbd
Follow us on Twitter and Facebook
Investors and
Media:
IR@canbiola.com
(516)
595-9544